Cargando…

Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis

Anti-transcriptional intermediary factor 1γ (anti-TIF1γ) antibody-positive dermatomyositis (DM) is strongly associated with cancer, although the mechanism of action is still unclear. We herein describe the first known case of an 80-year-old woman diagnosed with TIF1γ-positive primary pulmonary lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakanishi, Yu, Yamaguchi, Kakuhiro, Yoshida, Yusuke, Sakamoto, Shinjiro, Horimasu, Yasushi, Masuda, Takeshi, Nakashima, Taku, Miyamoto, Shintarou, Iwamoto, Hiroshi, Hirata, Shintaro, Fujitaka, Kazunori, Hamada, Hironobu, Sugiyama, Eiji, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662058/
https://www.ncbi.nlm.nih.gov/pubmed/32581161
http://dx.doi.org/10.2169/internalmedicine.4702-20
_version_ 1783609320268627968
author Nakanishi, Yu
Yamaguchi, Kakuhiro
Yoshida, Yusuke
Sakamoto, Shinjiro
Horimasu, Yasushi
Masuda, Takeshi
Nakashima, Taku
Miyamoto, Shintarou
Iwamoto, Hiroshi
Hirata, Shintaro
Fujitaka, Kazunori
Hamada, Hironobu
Sugiyama, Eiji
Hattori, Noboru
author_facet Nakanishi, Yu
Yamaguchi, Kakuhiro
Yoshida, Yusuke
Sakamoto, Shinjiro
Horimasu, Yasushi
Masuda, Takeshi
Nakashima, Taku
Miyamoto, Shintarou
Iwamoto, Hiroshi
Hirata, Shintaro
Fujitaka, Kazunori
Hamada, Hironobu
Sugiyama, Eiji
Hattori, Noboru
author_sort Nakanishi, Yu
collection PubMed
description Anti-transcriptional intermediary factor 1γ (anti-TIF1γ) antibody-positive dermatomyositis (DM) is strongly associated with cancer, although the mechanism of action is still unclear. We herein describe the first known case of an 80-year-old woman diagnosed with TIF1γ-positive primary pulmonary lymphoepithelioma-like carcinoma (LELC) coexisting with anti-TIF1γ antibody-positive DM. The diagnosis of LELC can only be made by a surgical lung biopsy, and not by a computed tomography-guided biopsy, because of heavy lymphocytic infiltration. This instructive case reaffirmed the importance of active screening for malignancy in patients with anti-TIF1γ antibody-positive DM. Interestingly, the results also suggested that the strong relationship which exists between anti-TIF1γ antibody-positive DM and cancer is potentially caused by tumor-derived TIF1γ.
format Online
Article
Text
id pubmed-7662058
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-76620582020-11-25 Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis Nakanishi, Yu Yamaguchi, Kakuhiro Yoshida, Yusuke Sakamoto, Shinjiro Horimasu, Yasushi Masuda, Takeshi Nakashima, Taku Miyamoto, Shintarou Iwamoto, Hiroshi Hirata, Shintaro Fujitaka, Kazunori Hamada, Hironobu Sugiyama, Eiji Hattori, Noboru Intern Med Case Report Anti-transcriptional intermediary factor 1γ (anti-TIF1γ) antibody-positive dermatomyositis (DM) is strongly associated with cancer, although the mechanism of action is still unclear. We herein describe the first known case of an 80-year-old woman diagnosed with TIF1γ-positive primary pulmonary lymphoepithelioma-like carcinoma (LELC) coexisting with anti-TIF1γ antibody-positive DM. The diagnosis of LELC can only be made by a surgical lung biopsy, and not by a computed tomography-guided biopsy, because of heavy lymphocytic infiltration. This instructive case reaffirmed the importance of active screening for malignancy in patients with anti-TIF1γ antibody-positive DM. Interestingly, the results also suggested that the strong relationship which exists between anti-TIF1γ antibody-positive DM and cancer is potentially caused by tumor-derived TIF1γ. The Japanese Society of Internal Medicine 2020-06-23 2020-10-15 /pmc/articles/PMC7662058/ /pubmed/32581161 http://dx.doi.org/10.2169/internalmedicine.4702-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakanishi, Yu
Yamaguchi, Kakuhiro
Yoshida, Yusuke
Sakamoto, Shinjiro
Horimasu, Yasushi
Masuda, Takeshi
Nakashima, Taku
Miyamoto, Shintarou
Iwamoto, Hiroshi
Hirata, Shintaro
Fujitaka, Kazunori
Hamada, Hironobu
Sugiyama, Eiji
Hattori, Noboru
Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
title Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
title_full Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
title_fullStr Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
title_full_unstemmed Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
title_short Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
title_sort coexisting tif1γ-positive primary pulmonary lymphoepithelioma-like carcinoma and anti-tif1γ antibody-positive dermatomyositis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662058/
https://www.ncbi.nlm.nih.gov/pubmed/32581161
http://dx.doi.org/10.2169/internalmedicine.4702-20
work_keys_str_mv AT nakanishiyu coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT yamaguchikakuhiro coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT yoshidayusuke coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT sakamotoshinjiro coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT horimasuyasushi coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT masudatakeshi coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT nakashimataku coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT miyamotoshintarou coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT iwamotohiroshi coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT hiratashintaro coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT fujitakakazunori coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT hamadahironobu coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT sugiyamaeiji coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis
AT hattorinoboru coexistingtif1gpositiveprimarypulmonarylymphoepitheliomalikecarcinomaandantitif1gantibodypositivedermatomyositis